Latest HBsAg Stories
Presented: Sunday, November 9, 2014, 5:00 pm Eastern - Hynes Convention Center, Boston, MA BOSTON, Nov.
In its May 2014 survey, polyDNA found that 36% of respondents wanted to know what complications can arise from a hepatitis B infection.
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
Data to be presented in April at the European Association for the Study of the Liver Meeting CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
INDIANAPOLIS, July 26, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has submitted a Premarket Approval Application (PMA) to the U.S.
Findings from two new studies presented today at the International Liver CongressTM confirm that there are options for clinicians to expand the pool of liver grafts for use in patients with liver disease.
PLEASANTON, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Roche Molecular Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food & Drug Administration (FDA) has approved the COBASÂ® AmpliPrep / COBASÂ® TaqManÂ® HBV Test v2.0 for use in the United States.
- A transitional zone between two communities containing the characteristic species of each.